BioCentury
ARTICLE | Company News

IQWiG backs Zytiga for additional indication

April 16, 2013 12:41 AM UTC

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Zytiga abiraterone from Johnson & Johnson (NYSE:JNJ) has "significant" additional benefit over "watchful waiting" to treat chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC) -- an indication approved by the European Commission in January. IQWiG said watchful waiting includes continuation of prior androgen deprivation therapy or a combination of androgen blockers with non-steroidal anti-androgen therapy. J&J has until May 6 to respond. A final benefit assessment from Germany's Federal Joint Committee (G-BA) is expected in early July. ...